zinc finger protein 124Genealiases: HZF-16 · HZF16 · ZK7
Q-omics provides the consensus-scored ZNF124 profile across patient tissues and cancer cell-line models. ZNF124 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ZNF124 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZNF124 RNA expression shows 21,096 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, KICH, and UVM as cancer lineages where ZNF124 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF124 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF124 survival associations across molecular data types. ZNF124 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF124 RNA expression–survival associations across cancer types. High ZNF124 expression shows unfavorable associations in LIHC, ACC and CESC, but favorable associations in KIRC, LAML and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ZNF124 RNA expression.
This table summarizes ZNF124 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF124. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF124 shows lower tumor expression in KICH and higher tumor expression in BLCA, HNSC, STAD, UCEC and BRCA. The KICH box plot shows higher ZNF124 RNA expression in normal versus tumor tissue (log2 FC = −1.213, t-test p < 0.001).
This table shows molecular features associated with ZNF124 in patient tissues and cancer cell lines. In patient samples, ZNF124 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF124 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
